Laboratory - Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases
Humana Medicare Advantage payment policy governing reimbursement for serum testing of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies and related laboratory biomarker procedures for specified neurologic conditions.
No material clinical or coverage changes in this revision.
Reimbursable and Non-reimbursable Testing
Reimbursable and non-reimbursable testing criteria
Covered when ALL of the following apply:
Reimbursable indications (ONE or more of):
- Blindness or vision loss
- Demyelinating disease
- Disease of spinal cord
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.